{"content":"<li class=\"n-box-item date-title\" data-end=\"1489809599\" data-start=\"1489723200\" data-txt=\"Sunday, December 22, 2019\">Friday, March 17, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3252090\" data-ts=\"1489787338\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252090-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/ARLZ-OLD' title='Aralez Pharmaceuticals Inc.'>ARLZ-OLD</a> <font color='green'>+5.3%</font>. <a href='https://seekingalpha.com/symbol/SFM' title='Sprouts Farmers Market'>SFM</a> <font color='green'>+4.5%</font>. <a href='https://seekingalpha.com/symbol/DEST' title='Destination Maternity Corporation'>DEST</a> <font color='green'>+3.8%</font>. <a href='https://seekingalpha.com/symbol/EXK' title='Endeavour Silver Corp.'>EXK</a> <font color='green'>+3.5%</font>. <a href='https://seekingalpha.com/symbol/MVIS' title='Microvision, Inc.'>MVIS</a> <font color='green'>+3.4%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color='red'>-15.9%</font>. <a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a> <font color='red'>-3.9%</font>. <a href='https://seekingalpha.com/symbol/VRAY' title='ViewRay'>VRAY</a> <font color='red'>-3.2%</font>. <a href='https://seekingalpha.com/symbol/ASBB' title='ASB Bancorp, Inc.'>ASBB</a> <font color='red'>-3.0%</font>. <a href='https://seekingalpha.com/symbol/RIC' title='Richmont Mines, Inc'>RIC</a> <font color='red'>-2.8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252090\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$ARLZ-OLD $SFM $DEST - After Hours Gainers / Losers https://seekingalpha.com/news/3252090-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3252090-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252088\" data-ts=\"1489786917\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DGSE\" target=\"_blank\">DGSE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252088-dgse-companies-expects-q1-profit-sharesplus-5_92-ah\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DGSE Companies expects Q1 profit; Shares +5.92% AH</a></h4><ul>     <li>DGSE (NYSEMKT:<a href='https://seekingalpha.com/symbol/DGSE' title='DGSE Companies, Inc'>DGSE</a>) <a href=\"https://seekingalpha.com/pr/16774829-dgse-companies-expects-first-quarter-profit\" target=\"_blank\">expects to post a profit</a> in the Q1 for the first time in four years.</li>     <li>The updated expectations was due to extraordinary gains in its retail business. The company also anticipates this turnaround to continue guiding the company toward higher revenues and regained profitability.</li><li>Shares&nbsp;<font color='green'>+5.92%</font>&nbsp;AH</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252088\" data-linked=\"DGSE Companies expects Q1 profit; Shares +5.92% AH\" data-tweet=\"$DGSE - DGSE Companies expects Q1 profit; Shares +5.92% AH https://seekingalpha.com/news/3252088-dgse-companies-expects-q1-profit-sharesplus-5_92-ah?source=tweet\" data-url=\"https://seekingalpha.com/news/3252088-dgse-companies-expects-q1-profit-sharesplus-5_92-ah\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252081\" data-ts=\"1489784061\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252081-weekly-etf-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weekly ETF Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/KOL' title='VanEck Vectors Coal ETF'>KOL</a> <font color='green'>+5.6%</font>. <a href='https://seekingalpha.com/symbol/EWY' title='iShares MSCI South Korea Capped ETF'>EWY</a> <font color='green'>+5.0%</font>. <a href='https://seekingalpha.com/symbol/URA' title='Global X Uranium ETF'>URA</a> <font color='green'>+4.9%</font>. <a href='https://seekingalpha.com/symbol/GDXJ' title='VanEck Vectors Junior Gold Miners ETF'>GDXJ</a> <font color='green'>+4.6%</font>. <a href='https://seekingalpha.com/symbol/DEM' title='WisdomTree Emerging Markets High Dividend ETF'>DEM</a> <font color='green'>+4.4%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/VXX' title='iPath S&P 500 VIX Short-Term Futures ETN'>VXX</a> <font color='red'>-7.1%</font>. <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a> <font color='red'>-3.1%</font>. <a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a> <font color='red'>-1.4%</font>. <a href='https://seekingalpha.com/symbol/XLV' title='Health Care Select Sect SPDR ETF'>XLV</a> <font color='red'>-1.1%</font>. <a href='https://seekingalpha.com/symbol/UUP' title='PowerShares DB USD Bull ETF'>UUP</a> <font color='red'>-1.0%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252081\" data-linked=\"Weekly ETF Gainers / Losers\" data-tweet=\"$KOL $EWY $URA - Weekly ETF Gainers / Losers https://seekingalpha.com/news/3252081-weekly-etf-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3252081-weekly-etf-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:54 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252064\" data-ts=\"1489779053\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADBE\" target=\"_blank\">ADBE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252064-wunderlich-securities-upgrades-adobe-systems-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wunderlich Securities upgrades Adobe Systems to Buy</a></h4><ul><li>From Hold post-Q1 2017 reporting,&nbsp;<a href=\"http://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Wunderlich+Securities+Upgrades+Adobe+%28ADBE%29+to+Buy/12679755.html\" target=\"_blank\">analyst Ryan MacDonald</a> cites Adobe Systems' (NASDAQ:<a href='https://seekingalpha.com/symbol/ADBE' title='Adobe Systems Incorporated'>ADBE</a>) ongoing high-level execution, sound market share and \"unmatched\" mix of revenue expansion and profitability, factors considered warranting premium valuation.</li><li>Elevates price target from $115 to $145 (among several&nbsp;<a href=\"https://www.tipranks.com/stocks/adbe\" target=\"_blank\">$140+ target raises</a>&nbsp;and buy-equivalent reiterations issued subsequent the report). Shares $127.69,&nbsp;<font color='green'>+4.36%</font>.</li><li>Yesterday (March 16, 2017): <a href=\"https://seekingalpha.com/news/3251820-adobe-systems-plus-4_2-percent-q1-2017-forecasts-positive\" target=\"_blank\">Adobe Systems +4.2%; Q1 2017, forecasts positive</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3252064\" data-linked=\"Wunderlich Securities upgrades Adobe Systems to Buy\" data-tweet=\"$ADBE - Wunderlich Securities upgrades Adobe Systems to Buy https://seekingalpha.com/news/3252064-wunderlich-securities-upgrades-adobe-systems-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3252064-wunderlich-securities-upgrades-adobe-systems-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252096\" data-ts=\"1489777525\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SND\" target=\"_blank\">SND</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252096-smart-sand-extends-post-earnings-gain-nowplus-16-in-two-days\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Smart Sand extends post-earnings gain, now +16% in two days</a></h4><ul>     <li>Fracking sand provider Smart Sand (<a href='https://seekingalpha.com/symbol/SND' title='Smart Sand'>SND</a> <font color='green'>+9.6%</font>) is 16% higher in two days after beating <a href=\"https://seekingalpha.com/news/3251659-smart-sand-beats-0_02-misses-revenue\" target=\"_blank\">Q4 earnings</a> expectations and reversing a year-ago net loss.</li><li>SND says Q4 sales of Northern White raw frac sand jumped 19% Q/Q and 156% Y/Y to 274K tons sold vs. 229.7K tons during Q3 and 107.2K tons during Q4 2015, while revenues rose 94% Y/Y to $29.5M, essentially in-line with analyst consensus; SND estimates 2017 capex of ~$55M.</li>     <li>Analysts at Johnson Rice today <a href=\"https://www.streetinsider.com/Analyst+PT+Change/Johnson+Rice+Upgrades+Smart+Sand+%28SND%29+to+Buy/12680240.html\" target=\"_blank\">upgraded</a> their investment call for SND to Buy from Accumulate and raised their stock price target by $1 to $21.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252096\" data-linked=\"Smart Sand extends post-earnings gain, now +16% in two days\" data-tweet=\"$SND - Smart Sand extends post-earnings gain, now +16% in two days https://seekingalpha.com/news/3252096-smart-sand-extends-post-earnings-gain-nowplus-16-in-two-days?source=tweet\" data-url=\"https://seekingalpha.com/news/3252096-smart-sand-extends-post-earnings-gain-nowplus-16-in-two-days\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252062\" data-ts=\"1489777227\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252062-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MVIS' title='Microvision, Inc.'>MVIS</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/NH' title='NantHealth'>NH</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/SITO' title='SITO Mobile, Ltd.'>SITO</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/AVID' title='Avid Technology, Inc.'>AVID</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/SCON' title='Superconductor Technologies Inc.'>SCON</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/QBAK' title='Qualstar Corporation'>QBAK</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/AXTI' title='AXT Inc'>AXTI</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/EXA' title='Exa Corporation'>EXA</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/VLTC' title='Voltari Corporation'>OTC:VLTC</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/SUNW' title='Sunworks, Inc.'>SUNW</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252062\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$MVIS $NH $SITO - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3252062-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3252062-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252059\" data-ts=\"1489775899\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JBS\" target=\"_blank\">JBS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252059-jbs-foods-and-brf-decline-amid-bribery-probe\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JBS Foods and BRF decline amid bribery probe</a></h4><ul><li>JBS Foods (<a href='https://seekingalpha.com/symbol/JBS' title='JBS Foods Inc'>JBS</a>) and BRF (<a href='https://seekingalpha.com/symbol/BRFFF' title='BRF S.A.'>OTC:BRFFF</a>) are under investigation in Brazil for taking part of a <a href=\"https://www.bloomberg.com/news/articles/2017-03-17/brazil-meat-producers-jbs-brf-probed-in-alleged-bribery-scheme\" target=\"_blank\">bribery scheme</a>, according to Bloomberg.</li><li>Brazilian media reports that the large police operation involves court orders and detention warrants.</li><li>JBS is&nbsp;<font color='red'>down 11%</font>&nbsp;in Sao Paulo trading and BRF is&nbsp;<font color='red'>8% lower</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252059\" data-linked=\"JBS Foods and BRF decline amid bribery probe\" data-tweet=\"$JBS $JBS $BRFFF - JBS Foods and BRF decline amid bribery probe https://seekingalpha.com/news/3252059-jbs-foods-and-brf-decline-amid-bribery-probe?source=tweet\" data-url=\"https://seekingalpha.com/news/3252059-jbs-foods-and-brf-decline-amid-bribery-probe\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252058\" data-ts=\"1489775281\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBR\" target=\"_blank\">PBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252058-brazil-oil-union-says-petrobras-divestment-still-on-hold\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Brazil oil union says Petrobras divestment still on hold</a></h4><ul>     <li>A regional oil workers' union in Brazil says an injunction freezing sales of assets by Petrobras (<a href='https://seekingalpha.com/symbol/PBR' title='Petrobras - Petroleo Brasileiro S.A.'>PBR</a> <font color='red'>-2.7%</font>) will <a href=\"http://www.reuters.com/article/petrobras-divestiture-idUSL2N1GU010\" target=\"_blank\">continue to block divestiture</a>, despite <a href=\"https://seekingalpha.com/news/3251509-brazils-audit-court-oks-petrobras-restart-asset-sales\" target=\"_blank\">this week's audit court ruling</a> allowing sales to go ahead.</li>     <li>The audit court ruling overturned an injunction that had suspended sales iand would allow PBR to proceed with the sale of a controlling stake in the BR Distribuidora fuel distribution unit, but the Sindipetro-AL/SE union says its injunction obtained in the state of Sergipe remains in effect.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252058\" data-linked=\"Brazil oil union says Petrobras divestment still on hold\" data-tweet=\"$PBR - Brazil oil union says Petrobras divestment still on hold https://seekingalpha.com/news/3252058-brazil-oil-union-says-petrobras-divestment-still-on-hold?source=tweet\" data-url=\"https://seekingalpha.com/news/3252058-brazil-oil-union-says-petrobras-divestment-still-on-hold\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:28 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252052\" data-ts=\"1489774147\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHAK\" target=\"_blank\">SHAK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252052-suntrust-seesplus-50-upside-on-shake-shack\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SunTrust sees +50% upside on Shake Shack</a></h4><ul>     <li>Shake Shack (NYSE:<a href='https://seekingalpha.com/symbol/SHAK' title='Shake Shack'>SHAK</a>) is&nbsp;<font color='green'>up 3.37%</font>&nbsp;after SunTrust Robinson Humphreys&nbsp;<a href=\"http://blogs.barrons.com/stockstowatchtoday/2017/03/17/shake-shack-not-done-yet/\" target=\"_blank\">calls out</a> upside of over 50% on the restaurant stock.</li>     <li>\"Tough year-ago compares in 1Q17 make SSS difficult to predict, but we view our flat SSS est. as achievable, and see risk to SSS decreasing sharply as compares ease starting in 2Q17,\" writes the SunTrust analyst team.</li><li>SunTrust think Shake Shack will open up 24 units this year vs. SHAK guidance for 22 to 23.&nbsp;The firm takes its price target to $50.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252052\" data-linked=\"SunTrust sees +50% upside on Shake Shack\" data-tweet=\"$SHAK - SunTrust sees +50% upside on Shake Shack https://seekingalpha.com/news/3252052-suntrust-seesplus-50-upside-on-shake-shack?source=tweet\" data-url=\"https://seekingalpha.com/news/3252052-suntrust-seesplus-50-upside-on-shake-shack\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252046\" data-ts=\"1489773614\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252046-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/DDC' title='Dominion Diamond Corporation'>DDC</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/WLB' title='Westmoreland Coal Co'>WLB</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/MTL' title='Mechel OAO'>MTL</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/DELT' title='Delta Technology Holdings Limited'>DELT</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/FF' title='FutureFuel Corp.'>FF</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/BIOA' title='BioAmber'>OTC:BIOA</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/SXCP' title='SunCoke Energy Partners'>SXCP</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/CDXC' title='ChromaDex Inc.'>CDXC</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/SXC' title='SunCoke Energy'>SXC</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/LXU' title='LSB Industries, Inc.'>LXU</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252046\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$DDC $WLB $MTL - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3252046-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3252046-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252036\" data-ts=\"1489772278\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIVN\" target=\"_blank\">FIVN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252036-five9-plus-6_2-upgraded-to-overweight-pacific-crest-securities\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Five9 +6.2%; upgraded to Overweight at Pacific Crest Securities</a></h4><ul><li>From Sector Weight previously, <a href=\"http://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Pacific+Crest+Upgrades+Five9%2C+Inc+%28FIVN%29+to+Overweight/12679528.html\" target=\"_blank\">analyst Brent Bracelin</a> forecasts potential tripling of revenue over the next five years, generated by opportunity to disrupt and supplant legacy on-premise competitors Avaya, Genesys and Aspect (grouping maintains approximately 50% market share). Price target $22.</li><li>Five9 (NASDAQ:<a href='https://seekingalpha.com/symbol/FIVN' title='Five9, Inc.'>FIVN</a>) $17.88.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252036\" data-linked=\"Five9 +6.2%; upgraded to Overweight at Pacific Crest Securities\" data-tweet=\"$FIVN - Five9 +6.2%; upgraded to Overweight at Pacific Crest Securities https://seekingalpha.com/news/3252036-five9-plus-6_2-upgraded-to-overweight-pacific-crest-securities?source=tweet\" data-url=\"https://seekingalpha.com/news/3252036-five9-plus-6_2-upgraded-to-overweight-pacific-crest-securities\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252021\" data-ts=\"1489770092\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252021-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/FAC' title='First Acceptance Corporation'>FAC</a> <font color='green'>+15%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AFSI' title='AmTrust Financial Services, Inc.'>AFSI</a> <font color='red'>-19%</font>. WAC <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/PN' title='Patriot National, Inc.'>PN</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/GLA' title='GlassBridge Enterprises, Inc.'>GLA</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/HIFS' title='Hingham Institution for Savings'>HIFS</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252021\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$FAC $AFSI $DHCP - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3252021-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3252021-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252022\" data-ts=\"1489769724\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBI\" target=\"_blank\">CBI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252022-cb-and-i-cut-to-hold-from-buy-argus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CB&amp;I cut to Hold from Buy at Argus</a></h4><ul>     <li>CB&amp;I (<a href='https://seekingalpha.com/symbol/CBI' title='Chicago Bridge & Iron Company'>CBI</a> <font color='red'>-1.9%</font>) is <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/17/03/9185817/argus-crossing-over-to-a-hold-rating-on-chicago-bridge-i\" target=\"_blank\">downgraded</a> to Hold from Buy at Argus after posting a sharp <a href=\"https://seekingalpha.com/news/3247359-chicago-bridge-and-iron-misses-0_60-misses-revenue\" target=\"_blank\">Q4 earnings miss</a> and amid energy sector weakness.</li>     <li>CBI has faced challenges from energy sector weakness over the last two years, and Argus says it is unlikely to see a sudden rebound in revenue or earnings, adding that the company has been divesting assets in recent quarters, taking nine-figure losses along the way and weakening the balance sheet.</li>     <li>Shares have slumped 6% YTD, with the weakness reflecting CBI's current business challenges as well as uncertainties related to the legal dispute with Westinghouse Electric, which bought the company&rsquo;s nuclear construction business in late 2015.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252022\" data-linked=\"CB&amp;I cut to Hold from Buy at Argus\" data-tweet=\"$CBI - CB&amp;I cut to Hold from Buy at Argus https://seekingalpha.com/news/3252022-cb-and-i-cut-to-hold-from-buy-argus?source=tweet\" data-url=\"https://seekingalpha.com/news/3252022-cb-and-i-cut-to-hold-from-buy-argus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252020\" data-ts=\"1489769628\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VUZI\" target=\"_blank\">VUZI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252020-vuzixminus-10_35-q4-2016-off-records-1_1m-write-down\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vuzix -10.35%; Q4 2016 off, records $1.1M write-down</a></h4><ul><li><strong><a href=\"https://seekingalpha.com/news/3251892-vuzix-misses-revenue\" target=\"_blank\">Q4 2016 results</a></strong> &ndash; revenue $0.62M (+14.8% Y/Y,&nbsp;<font color='red'>$0.87M below estimates</font>), net loss $6.3M (vs. $3.5M Y/Y)</li><li><strong>Other developments</strong> &ndash; Loss on inventory of $1,124,401 registered (vs. $0 Y/Y), attributed to management decision to lower retail pricing of iWear inventory (from $499 to $299). Vuzix further notes it's targeting a shift away from VR-based iWear offerings to focus greater on enterprise market opportunities.</li><li>Shares (NASDAQ:<a href='https://seekingalpha.com/symbol/VUZI' title='Vuzix Corp'>VUZI</a>) $6.46.</li><li><a href=\"https://seekingalpha.com/pr/16774178-vuzix-provides-business-update-reports-full-year-fourth-quarter-2016-financial-results\" target=\"_blank\">Press release</a>&nbsp;/ <a href=\"https://seekingalpha.com/filing/3465148\" target=\"_blank\">8-K</a></li><li>Yesterday (March 16, 2017):&nbsp;<a href=\"https://seekingalpha.com/news/3251867-vuzix-minus-4_2-percent-hours-notes-material-weakness-ongoing-december-2016\" target=\"_blank\">Vuzix -4.2% after hours, notes material weakness ongoing as of December 2016</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3252020\" data-linked=\"Vuzix -10.35%; Q4 2016 off, records $1.1M write-down\" data-tweet=\"$VUZI - Vuzix -10.35%; Q4 2016 off, records $1.1M write-down https://seekingalpha.com/news/3252020-vuzixminus-10_35-q4-2016-off-records-1_1m-write-down?source=tweet\" data-url=\"https://seekingalpha.com/news/3252020-vuzixminus-10_35-q4-2016-off-records-1_1m-write-down\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252018\" data-ts=\"1489769266\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252018-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color='green'>+38%</font>. <a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a> <font color='green'>+35%</font>. <a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a> <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/ABUS' title='Arbutus Biopharma Corp'>ABUS</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/AVXS' title='AveXis'>AVXS</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/CLBS' title='Caladrius Biosciences, Inc.'>CLBS</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/FAC' title='First Acceptance Corporation'>FAC</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/NH' title='NantHealth'>NH</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/CGIX' title='Cancer Genetics, Inc.'>CGIX</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/XGTI' title='xG Technology, Inc.'>XGTI</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/INNL' title='Innocoll'>INNL</a> <font color='red'>-26%</font>. <a href='https://seekingalpha.com/symbol/BIOA' title='BioAmber'>OTC:BIOA</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/ESPR' title='Esperion Therapeutics'>ESPR</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/AFSI' title='AmTrust Financial Services, Inc.'>AFSI</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/QBAK' title='Qualstar Corporation'>QBAK</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/CRMD' title='CorMedix Inc.'>CRMD</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/ADAT' title='Authentidate Holding Corp.'>ADAT</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/MDCO' title='The Medicines Company'>MDCO</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/AXTI' title='AXT Inc'>AXTI</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/CAL' title='Caleres, Inc.'>CAL</a> <font color='red'>-13%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252018\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$PULM $EKSO $DFFN - Midday Gainers / Losers https://seekingalpha.com/news/3252018-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3252018-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252017\" data-ts=\"1489768609\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EFOI\" target=\"_blank\">EFOI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252017-energy-focus-picks-port-new-cfo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy Focus picks Port as new CFO</a></h4><ul>     <li>Energy Focus (<a href='https://seekingalpha.com/symbol/EFOI' title='Energy Focus, Inc.'>EFOI</a> <font color='green'>+8.9%</font>) appoints controller and former interim CFO Michael Port as its <a href=\"https://seekingalpha.com/pr/16774492-energy-focus-appoints-controller-chief-financial-officer\" target=\"_blank\">new CFO</a>, replacing Bradley White, who is leaving the company to pursue other opportunities.</li>     <li>Port has been EFOI's controller since July 2015, and was interim CFO from August to December 2016, after spending five years as a consultant with Resources Global Professionals.</li>     <li>White has been CFO only since December; he had been CFO of EngagePoint Inc. since 2015 following financial roles at National Grid USA and Unisys.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252017\" data-linked=\"Energy Focus picks Port as new CFO\" data-tweet=\"$EFOI - Energy Focus picks Port as new CFO https://seekingalpha.com/news/3252017-energy-focus-picks-port-new-cfo?source=tweet\" data-url=\"https://seekingalpha.com/news/3252017-energy-focus-picks-port-new-cfo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252015\" data-ts=\"1489767786\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CELP\" target=\"_blank\">CELP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252015-cypress-energy-partners-downgraded-to-hold-from-buy-stifel\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cypress Energy Partners downgraded to Hold from Buy at Stifel</a></h4><ul><li>Cypress Energy Partners (<a href='https://seekingalpha.com/symbol/CELP' title='Cypress Energy Partners, L.P.'>CELP</a> <font color='green'>+1.9%</font>) is <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Stifel+Downgrades+Cypress+Energy+Partners+%28CELP%29+to+Hold/12679893.html\" target=\"_blank\">downgraded</a> to Hold from Buy with a $9.50 price target, cut from $14, at Stifel, even after shares had slumped 26% in two days following <a href=\"https://seekingalpha.com/news/3251177-cypress-energy-eps-line-misses-revenue\" target=\"_blank\">Q4 results</a> that included lower than expected revenues.</li><li>Stifel believes a 50% distribution cut is inevitable, as CELP has not been able to make a value accretive acquisition to help drive distributable cash flow in-line with the ~$0.40/quarter distribution.</li><li>A 50% distribution cut combined with a $9.50 target price would mean an 8%-plus yield, which the firm notes is still a nice annual overall return, and units could enjoy a big pop if the distribution cut does not happen.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252015\" data-linked=\"Cypress Energy Partners downgraded to Hold from Buy at Stifel\" data-tweet=\"$CELP - Cypress Energy Partners downgraded to Hold from Buy at Stifel https://seekingalpha.com/news/3252015-cypress-energy-partners-downgraded-to-hold-from-buy-stifel?source=tweet\" data-url=\"https://seekingalpha.com/news/3252015-cypress-energy-partners-downgraded-to-hold-from-buy-stifel\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252013\" data-ts=\"1489767206\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252013-dollar-gives-up-post-election-gains\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dollar gives up most post-election gains</a></h4><ul><li>This just in from Bloomberg: Headed for one of its worst weeks of the year, the dollar today touched its lowest level since Nov. 11.</li><li>The big event this week, of course, was the Fed's \"dovish rate hike\" on Wednesday, at which the centra bank disappointed dollar bulls hoping for indications of a plan for a sped up pace of rate hikes.</li><li>Morgan Stanley also takes note of lessened political risks in Europe after the status quo prevailed over the nationalists in Dutch elections.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/UUP' title='PowerShares DB USD Bull ETF'>UUP</a>, <a href='https://seekingalpha.com/symbol/UDN' title='PowerShares DB USD Bear ETF'>UDN</a>, <a href='https://seekingalpha.com/symbol/USDU' title='WisdomTree Bloomberg U.S. Dollar Bullish ETF'>USDU</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3252013\" data-linked=\"Dollar gives up most post-election gains\" data-tweet=\"$UUP $UDN $USDU - Dollar gives up most post-election gains https://seekingalpha.com/news/3252013-dollar-gives-up-post-election-gains?source=tweet\" data-url=\"https://seekingalpha.com/news/3252013-dollar-gives-up-post-election-gains\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>47&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252012\" data-ts=\"1489767041\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252012-healthcare-top-5-gainers-losers-of-12-10-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 12:10 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color='green'>+40%</font>. <a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/CLBS' title='Caladrius Biosciences, Inc.'>CLBS</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/AVXS' title='AveXis'>AVXS</a> <font color='green'>+18%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CRMD' title='CorMedix Inc.'>CRMD</a> <font color='red'>-26%</font>. <a href='https://seekingalpha.com/symbol/INNL' title='Innocoll'>INNL</a> <font color='red'>-24%</font>. <a href='https://seekingalpha.com/symbol/ESPR' title='Esperion Therapeutics'>ESPR</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/MDCO' title='The Medicines Company'>MDCO</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/ADPT' title='Adeptus Health'>ADPT</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252012\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 12:10 PM\" data-tweet=\"$PULM $DFFN $EKSO - Healthcare - Top 5 Gainers / Losers as of 12:10 PM https://seekingalpha.com/news/3252012-healthcare-top-5-gainers-losers-of-12-10-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3252012-healthcare-top-5-gainers-losers-of-12-10-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252010\" data-ts=\"1489766656\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252010-consumers-top-5-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumers - Top 5 Gainers / Losers as of 12:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/EFOI' title='Energy Focus, Inc.'>EFOI</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CAL' title='Caleres, Inc.'>CAL</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/VRTV' title='Veritiv'>VRTV</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/VUZI' title='Vuzix Corp'>VUZI</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/BRFS' title='BRF-Brasil Foods S.A.'>BRFS</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/SNAK' title='Inventure Foods, Inc.'>SNAK</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252010\" data-linked=\"Consumers - Top 5 Gainers / Losers as of 12:00 PM\" data-tweet=\"$EFOI $CAL $VRTV - Consumers - Top 5 Gainers / Losers as of 12:00 PM https://seekingalpha.com/news/3252010-consumers-top-5-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3252010-consumers-top-5-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252007\" data-ts=\"1489766279\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VSLR\" target=\"_blank\">VSLR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252007-vivint-solarplus-8-on-smaller-expected-q4-loss-upbeat-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vivint Solar +8% on smaller than expected Q4 loss, upbeat outlook</a></h4><ul>     <li>Vivint Solar (<a href='https://seekingalpha.com/symbol/VSLR' title='Vivint Solar'>VSLR</a> <font color='green'>+8.1%</font>) surges higher after <a href=\"https://seekingalpha.com/news/3251785-vivint-solar-beats-0_04-misses-revenue\" target=\"_blank\">Q4 results</a> include a smaller than expected loss for the third straight quarter and a ~160% Y/Y revenue increase.</li>     <li>VSLR says it installed 47 MW during Q4, its lowest level since Q1 2015, and forecasts 43-46 MW in installations for Q1 2017, but 57 MW booked during Q4 means its <a href=\"https://pv-magazine-usa.com/2017/03/16/vivint-solar-installations-decline-in-q4/\" target=\"_blank\">backlog is growing</a>, and the company expects installations to increase  during the summer months.</li>     <li>VSLR lowered its installed cost per watt during Q4 to $3.08, and expects to bring costs per watt down to $2.95-$3.05 during Q1.</li>     <li>For FY 2017, VSLR expects 210-230 MW installations at a cost per watt of $2.82-$2.94.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252007\" data-linked=\"Vivint Solar +8% on smaller than expected Q4 loss, upbeat outlook\" data-tweet=\"$VSLR - Vivint Solar +8% on smaller than expected Q4 loss, upbeat outlook https://seekingalpha.com/news/3252007-vivint-solarplus-8-on-smaller-expected-q4-loss-upbeat-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3252007-vivint-solarplus-8-on-smaller-expected-q4-loss-upbeat-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252006\" data-ts=\"1489765347\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZSAN\" target=\"_blank\">ZSAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252006-zosano-pharma-lower-after-pricing-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zosano Pharma lower after pricing share offering</a></h4><ul> <li>Zosano Pharma (<a href='https://seekingalpha.com/symbol/ZSAN' title='Zosano Pharma'>ZSAN</a> <font color='red'>-7%</font>) prices its public offering of 17M shares at $1.50 per share.</li><li>The company expects to generate&nbsp;proceeds of $25.5M before fees are deducted.</li><li>The offering is expected to close around March 23.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16774496-zosano-announces-pricing-public-offering-common-stock\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3252006\" data-linked=\"Zosano Pharma lower after pricing share offering\" data-tweet=\"$ZSAN - Zosano Pharma lower after pricing share offering https://seekingalpha.com/news/3252006-zosano-pharma-lower-after-pricing-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3252006-zosano-pharma-lower-after-pricing-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252005\" data-ts=\"1489765107\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MULE\" target=\"_blank\">MULE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252005-mulesoft-opens-42_6-over-initial-offer-pricing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MuleSoft opens 42.6% over initial offer pricing</a></h4><ul><li>Having yesterday&nbsp;<a href=\"https://seekingalpha.com/filing/3464701\" target=\"_blank\">priced at $17</a>, shares in <a href=\"https://www.mulesoft.com/\" target=\"_blank\">MuleSoft</a>&nbsp;(NYSE:<a href='https://seekingalpha.com/symbol/MULE' title='MuleSoft'>MULE</a>) are to this point in strong debut, trading higher by approximately&nbsp;<font color='green'>50%+</font>&nbsp;(currently $25.40, open $24.25).</li><li>The operation, founded in 2006, facilitates the creation of networks connected across data, applications and hardware devices primarily through API-based solutions.</li><li><a href=\"https://blogs.mulesoft.com/biz/mulesoft/mulesoft-ipo/\" target=\"_blank\">Blog post</a> [MuleSoft]</li></ul><div class=\"tiny-share-widget\" data-id=\"3252005\" data-linked=\"MuleSoft opens 42.6% over initial offer pricing\" data-tweet=\"$MULE - MuleSoft opens 42.6% over initial offer pricing https://seekingalpha.com/news/3252005-mulesoft-opens-42_6-over-initial-offer-pricing?source=tweet\" data-url=\"https://seekingalpha.com/news/3252005-mulesoft-opens-42_6-over-initial-offer-pricing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3251994\" data-ts=\"1489760617\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STML\" target=\"_blank\">STML</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3251994-stemlineminus-4_5-after-results-another-patient-death\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stemline -4.5% after results, another patient death</a></h4><ul><li><a href=\"https://seekingalpha.com/filing/3464258\" target=\"_blank\">In its 10-K filed</a> alongside <a href=\"https://seekingalpha.com/news/3251900-stemline-therapeutics-misses-0_01-beats-revenue\" target=\"_blank\">Q4 earnings</a> this morning, Stemline Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/STML' title='Stemline Therapeutics'>STML</a>) disclosed another patient death in the Phase 2 trial of SL-401.</li><li>Shares were down as much as 20% in premarket action, but currently&nbsp;<font color='red'>off just 4.5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3251994\" data-linked=\"Stemline -4.5% after results, another patient death\" data-tweet=\"$STML - Stemline -4.5% after results, another patient death https://seekingalpha.com/news/3251994-stemlineminus-4_5-after-results-another-patient-death?source=tweet\" data-url=\"https://seekingalpha.com/news/3251994-stemlineminus-4_5-after-results-another-patient-death\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3251991\" data-ts=\"1489760048\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAL\" target=\"_blank\">CAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3251991-caleres-slumps-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Caleres slumps after earnings</a></h4><ul>     <li>Caleres (<a href='https://seekingalpha.com/symbol/CAL' title='Caleres, Inc.'>CAL</a> <font color='red'>-12.3%</font>) trades lower after reporting <a href=\"https://seekingalpha.com/pr/16773970-caleres-reports-fourth-quarter-fiscal-2016-results\" target=\"_blank\">Q4 results</a> amid what it calls a \"promotional and challenging\" retail environment.</li> <li>Same-store sales were up 0.3% for the Famous Footwear chain during the quarter to miss the consensus estimate for a 2.3% gain.</li>     <li>Shares of Caleres are at their lowest level since November.</li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3251815-caleres-misses-0_05-beats-revenue\" target=\"_blank\">Caleres misses by $0.05, beats on revenue</a> (March 16)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3251991\" data-linked=\"Caleres slumps after earnings\" data-tweet=\"$CAL - Caleres slumps after earnings https://seekingalpha.com/news/3251991-caleres-slumps-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3251991-caleres-slumps-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3251990\" data-ts=\"1489759771\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3251990-mizuho-securities-initiates-snap-neutral\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mizuho Securities initiates Snap at Neutral</a></h4><ul><li>Amid the gradual retracing of Snap (<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a> <font color='red'>-2.4%</font>) shares in the direction of its initial $17 offering price (currently $19.42), <a href=\"http://www.streetinsider.com/Analyst+Comments/Mizuho+Securities+Starts+Snap+Inc+%28SNAP%29+at+Neutral/12679451.html\" target=\"_blank\">analyst Neil Doshi</a>, setting $20 target, notes execution on user growth and engagement is necessary to warrant present valuation while competition for both <a href=\"http://blogs.barrons.com/techtraderdaily/2017/03/17/tech-today-dump-aws-vuzix-drops-facebooks-monetization/\" target=\"_blank\">users and advertising dollars</a> escalates.</li><li>Notes EV/DAU of roughly $134 at the $17 offering price is approximately 2.2x greater than Facebook's cost for WhatsApp and 4.5x that of the price it paid for Instagram, properties with, at those points, materially more rapid growth than Snap.</li></ul><div class=\"tiny-share-widget\" data-id=\"3251990\" data-linked=\"Mizuho Securities initiates Snap at Neutral\" data-tweet=\"$SNAP - Mizuho Securities initiates Snap at Neutral https://seekingalpha.com/news/3251990-mizuho-securities-initiates-snap-neutral?source=tweet\" data-url=\"https://seekingalpha.com/news/3251990-mizuho-securities-initiates-snap-neutral\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3251989\" data-ts=\"1489759644\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TXRH\" target=\"_blank\">TXRH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3251989-upside-seen-for-texas-roadhouse\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Upside seen for Texas Roadhouse</a></h4><ul> <li>BTIG Research upgrades Texas Roadhouse (<a href='https://seekingalpha.com/symbol/TXRH' title='Texas Roadhouse, Inc.'>TXRH</a> <font color='green'>+3.5%</font>) to Buy from Neutral.</li> <li>The firm lifts its price target to $50, repping 17% upside potential.</li> <li>BTIG on TXRH: \"We believe heavy promotional activity drowned out Texas Roadhouse&rsquo;s consistent value proposition and that as this activity subsides, same-store sales should improve throughout the year. We believe that at current levels, expectations have been appropriately reset and the combination of consistent unit growth and a potential sales acceleration lead to our more positive view.\"</li><li>Shares of Texas Roadhouse have been in a gentle uptrend since bottoming out at $37.23 in late February.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3251989\" data-linked=\"Upside seen for Texas Roadhouse\" data-tweet=\"$TXRH - Upside seen for Texas Roadhouse https://seekingalpha.com/news/3251989-upside-seen-for-texas-roadhouse?source=tweet\" data-url=\"https://seekingalpha.com/news/3251989-upside-seen-for-texas-roadhouse\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3251980\" data-ts=\"1489757822\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMGN\" target=\"_blank\">AMGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3251980-amgenminus-6-mdcominus-22-esprminus-30-after-repatha-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amgen -6%, MDCO -22%, ESPR -30% after Repatha data</a></h4><ul><li><a href=\"http://investors.amgen.com/phoenix.zhtml?c=61656&amp;p=irol-newsArticle&amp;ID=2254800\" target=\"_blank\">The data from the $1B+ study of Repatha</a> look good - heart risks cut by 15% on the primary endpoint, and a 20% reduction in the key secondary endpoint of reduction or risk of first heart attack, stroke, or cardiovascular death.</li><li>Investors, however, were hoping for an upside surprise of something more than 20%.</li><li>Then there's costs - north of $14K per year. Insurers <a href=\"https://www.nytimes.com/2017/03/17/health/cholesterol-drugs-repatha-amgen-pcsk9-inhibitors.html?hp&amp;action=click&amp;pgtype=Homepage&amp;clickSource=story-heading&amp;module=first-column-region&amp;region=top-news&amp;WT.nav=top-news&amp;_r=1\" target=\"_blank\">are naturally reluctant</a> to pay for the drug without evidence is protects high-risk patients from heart attacks and strokes.</li><li>Amgen (<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color='red'>-6%</font>), Esperion (<a href='https://seekingalpha.com/symbol/ESPR' title='Esperion Therapeutics'>ESPR</a> <font color='red'>-29.5%</font>), The Medicines Company (<a href='https://seekingalpha.com/symbol/MDCO' title='The Medicines Company'>MDCO</a> <font color='red'>-22.1%</font>), Alnylam Pharma (<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a> <font color='red'>-6%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3251980\" data-linked=\"Amgen -6%, MDCO -22%, ESPR -30% after Repatha data\" data-tweet=\"$AMGN $AMGN $ESPR - Amgen -6%, MDCO -22%, ESPR -30% after Repatha data https://seekingalpha.com/news/3251980-amgenminus-6-mdcominus-22-esprminus-30-after-repatha-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3251980-amgenminus-6-mdcominus-22-esprminus-30-after-repatha-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>63&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3251982\" data-ts=\"1489757821\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SEAS\" target=\"_blank\">SEAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3251982-seaworld-entertainment-slides-off-of-citi-gloom\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SeaWorld Entertainment slides off of Citi gloom</a></h4><ul> <li>Citi cuts SeaWorld Entertainment (<a href='https://seekingalpha.com/symbol/SEAS' title='SeaWorld Entertainment Inc.'>SEAS</a> <font color='red'>-4%</font>) to a Sell rating on concerns that Street EBITDA estimates may be too high.</li> <li>The firm expects 2017 EBITDA of $339M for the theme park operator vs. $357M consensus.</li> <li>The <a href=\"http://247wallst.com/investing/2017/03/17/top-analyst-upgrades-and-downgrades-adobe-barclays-dean-foods-netflix-simon-property-snap-vertex-and-more/\" target=\"_blank\">price target</a> from Citi on SEAS goes to $15 from $19.</li> <li>SeaWorld has flirted with the $20 level several times, but hasn't closed over the threshold since last April.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3251982\" data-linked=\"SeaWorld Entertainment slides off of Citi gloom\" data-tweet=\"$SEAS - SeaWorld Entertainment slides off of Citi gloom https://seekingalpha.com/news/3251982-seaworld-entertainment-slides-off-of-citi-gloom?source=tweet\" data-url=\"https://seekingalpha.com/news/3251982-seaworld-entertainment-slides-off-of-citi-gloom\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3251977\" data-ts=\"1489756906\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3251977-netflix-shys-away-from-all-time-high-what-next\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Netflix shys away from all-time high, what next?</a></h4><ul> <li>Netflix (NASDAQ:<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a>) is <font color='red'>down 1.03%</font> in premarket action as shares back away from the all-time of $146.50 printed yesterday.</li> <li>M Science is out with a cautious take on Q1 subscriber data, according to Bloomberg. The firm holds some weight with Netflix sentiment due to its data-heavy analysis of consumer trends.</li> <li>Shares of Netflix are up 17% YTD and have jumped 48% over the last 52 weeks.</li><li>More: There's a pretty good debate on the upside potential for Netflix from here in the comment stream of an&nbsp;<a href=\"https://seekingalpha.com/article/4054261-netflix-plata-o-plomo\" target=\"_blank\">article</a>&nbsp;posted last week from SA contributor Celeritas Investments.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3251977\" data-linked=\"Netflix shys away from all-time high, what next?\" data-tweet=\"$NFLX - Netflix shys away from all-time high, what next? https://seekingalpha.com/news/3251977-netflix-shys-away-from-all-time-high-what-next?source=tweet\" data-url=\"https://seekingalpha.com/news/3251977-netflix-shys-away-from-all-time-high-what-next\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3251974\" data-ts=\"1489756604\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3251974-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul> <li><a href='https://seekingalpha.com/symbol/CRMD' title='CorMedix Inc.'>CRMD</a> <font color='red'>-24%</font> on FY earnings.</li><li><a href='https://seekingalpha.com/symbol/MDCO' title='The Medicines Company'>MDCO</a> <font color='red'>-22%</font> on Trump's 20% budget cut for National Institutes of Health.</li><li><a href='https://seekingalpha.com/symbol/STML' title='Stemline Therapeutics'>STML</a> <font color='red'>-19%</font> on Q4 earnings.</li><li><a href='https://seekingalpha.com/symbol/ESPR' title='Esperion Therapeutics'>ESPR</a> <font color='red'>-16%</font> on Trump's 20% budget cut for National Institutes of Health.</li><li><a href='https://seekingalpha.com/symbol/INNL' title='Innocoll'>INNL</a> <font color='red'>-15%</font> on Q4 earnings.</li><li><a href='https://seekingalpha.com/symbol/VRTV' title='Veritiv'>VRTV</a> <font color='red'>-9%</font> continuing its two-day losing streak on Q4 earnings.</li><li><a href='https://seekingalpha.com/symbol/VUZI' title='Vuzix Corp'>VUZI</a> <font color='red'>-8%</font> on Q4 earnings.</li><li><a href='https://seekingalpha.com/symbol/EDIT' title='Editas Medicine'>EDIT</a> <font color='red'>-7%</font> on lower price of secondary offering.</li><li><a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color='red'>-6%</font> on Trump's 20% budget cut for National Institutes of Health.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3251974\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$CRMD $MDCO $STML - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3251974-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3251974-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3251970\" data-ts=\"1489756294\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRMD\" target=\"_blank\">CRMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3251970-cormedix-crushed-after-warning-on-cash\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CorMedix crushed after warning on cash</a></h4><ul> <li>CorMedix (NYSEMKT:<a href='https://seekingalpha.com/symbol/CRMD' title='CorMedix Inc.'>CRMD</a>) plunges after some frank talk from the company on its ability to fund itself.</li> <li>\"Our commercial operations have not generated sufficient revenues to enable profitability.\"</li> <li>\"We will need additional funding to complete the hemodialysis clinical trial in the U.S. which commenced in December 2015 as well as to initiate the planned Phase 3 clinical trial in oncology patients with catheters.\"</li> <li>The company is seeking a funding partner, but warns it may have to scale back operations.</li> <li><a href=\"https://seekingalpha.com/filing/3463711\" target=\"_blank\">SEC Form 10-K</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3251930-cormedix-beats-0_06-beats-revenue\" target=\"_blank\">CorMedix beats by $0.06, beats on revenue</a> (March 17)</li> <li>CRMD <font color='red'>-23.67%</font> premarket to $1.58.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3251970\" data-linked=\"CorMedix crushed after warning on cash\" data-tweet=\"$CRMD - CorMedix crushed after warning on cash https://seekingalpha.com/news/3251970-cormedix-crushed-after-warning-on-cash?source=tweet\" data-url=\"https://seekingalpha.com/news/3251970-cormedix-crushed-after-warning-on-cash\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3251969\" data-ts=\"1489756163\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3251969-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul> <li><a href='https://seekingalpha.com/symbol/CLBS' title='Caladrius Biosciences, Inc.'>CLBS</a> <font color='green'>+53%</font> on sale of  80.1% stake in its PCT subsidiary.</li><li><a href='https://seekingalpha.com/symbol/ABUS' title='Arbutus Biopharma Corp'>ABUS</a> <font color='green'>+14%</font> on licensing deal with Alexion.</li><li><a href='https://seekingalpha.com/symbol/VIVE' title='Viveve Medical, Inc.'>VIVE</a> <font color='green'>+6%</font> on capital raise.</li><li><a href='https://seekingalpha.com/symbol/ADBE' title='Adobe Systems Incorporated'>ADBE</a> <font color='green'>+5%</font> on Q4 earnings.</li><li><a href='https://seekingalpha.com/symbol/ESEA' title='Euroseas Ltd.'>ESEA</a> <font color='green'>+5%</font> on improving shipping rates.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3251969\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$CLBS $ABUS $VIVE - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3251969-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3251969-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3251965\" data-ts=\"1489755220\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVXS\" target=\"_blank\">AVXS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3251965-avexis-soars-after-positive-phase-1-trial-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AveXis soars after positive Phase 1 trial results</a></h4><ul>     <li>AveXis (NASDAQ:<a href='https://seekingalpha.com/symbol/AVXS' title='AveXis'>AVXS</a>) pops after positive results from a Phase 1 trial of AVXS-101 in spinal muscular atrophy Type 1.</li>     <li>The company says no new treatment-related safety or tolerability findings resulted from the trial.</li>     <li>AveXis also reported Q4 results yesterday, which included a cash position of $240M at the end of 2016. A net loss of $25.4M was reported for the quarter.</li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3251818-avexis-misses-0_12\" target=\"_blank\">AveXis misses by $0.12</a> (March 16)</li>        <li>Source: <a href=\"https://seekingalpha.com/pr/16773932-avexis-reports-topline-results-phase-1-trial-avxsminus-101-sma-type-1-fourth-quarter-full\" target=\"_blank\">Press Release</a></li>  <li>AVXS  <font color='green'>+11.29%</font> premarket to  $81.00.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3251965\" data-linked=\"AveXis soars after positive Phase 1 trial results\" data-tweet=\"$AVXS - AveXis soars after positive Phase 1 trial results https://seekingalpha.com/news/3251965-avexis-soars-after-positive-phase-1-trial-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3251965-avexis-soars-after-positive-phase-1-trial-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3251963\" data-ts=\"1489755033\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GIMO\" target=\"_blank\">GIMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3251963-gigamonplus-3_35-upgraded-to-outperform-jmp-securities\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gigamon +3.35%; upgraded to Outperform at JMP Securities</a></h4><ul><li>From Market Perform, <a href=\"http://www.streetinsider.com/Analyst+Comments/JMP+Securities+Upgrades+Gigamon+%28GIMO%29+to+Market+Outperform/12679322.html\" target=\"_blank\">analyst Erik Suppiger</a> cites channel discourse indicating ongoing strength in competitive positioning and in demand for network visibility, while also highlighting record Q4 2016 customer additions with the view greater expansion and diversification remain opportunities.</li><li>Price target $45. Gigamon (NYSE:<a href='https://seekingalpha.com/symbol/GIMO' title='Gigamon, Inc.'>GIMO</a>) $37.</li></ul><div class=\"tiny-share-widget\" data-id=\"3251963\" data-linked=\"Gigamon +3.35%; upgraded to Outperform at JMP Securities\" data-tweet=\"$GIMO - Gigamon +3.35%; upgraded to Outperform at JMP Securities https://seekingalpha.com/news/3251963-gigamonplus-3_35-upgraded-to-outperform-jmp-securities?source=tweet\" data-url=\"https://seekingalpha.com/news/3251963-gigamonplus-3_35-upgraded-to-outperform-jmp-securities\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3251960\" data-ts=\"1489754676\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABUS\" target=\"_blank\">ABUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3251960-arbutus-biopharma-and-alexion-in-new-licensing-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arbutus Biopharma and Alexion in new licensing deal</a></h4><ul> <li>Arbutus Biopharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ABUS' title='Arbutus Biopharma Corp'>ABUS</a>) <font color='green'>jumps 8.4%</font> in premarket trading after the company licenses lipid nanoparticle technology to Alexion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ALXN' title='Alexion Pharmaceuticals, Inc.'>ALXN</a>).</li> <li>Deal terms: \"Alexion will pay Arbutus $7.5 million upfront, and payments of up to $75 million for achievement of development, regulatory, and commercial milestones, as well as single digit royalties. In addition, Arbutus will conduct technology development and provide manufacturing and regulatory support for the rapid advancement of Alexion's mRNA product candidate.\"</li> <li>Source: <a href=\"https://seekingalpha.com/pr/16774051-arbutus-licenses-lnp-delivery-technology-alexion-use-single-messenger-rna-product-candidate\" target=\"_blank\">Press Release</a></li>  </ul><div class=\"tiny-share-widget\" data-id=\"3251960\" data-linked=\"Arbutus Biopharma and Alexion in new licensing deal\" data-tweet=\"$ABUS $ABUS $ALXN - Arbutus Biopharma and Alexion in new licensing deal https://seekingalpha.com/news/3251960-arbutus-biopharma-and-alexion-in-new-licensing-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3251960-arbutus-biopharma-and-alexion-in-new-licensing-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3251959\" data-ts=\"1489754375\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIVE\" target=\"_blank\">VIVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3251959-viveve-medicalplus-3-after-upsizing-capital-raise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Viveve Medical +3% after upsizing capital raise</a></h4><ul><li>The company <a href=\"https://seekingalpha.com/pr/16774379-viveve-announces-pricing-public-offering-shares-common-stock\" target=\"_blank\">sold 7.5M shares</a> at $4 each. The underwriters have a greenshoe option to buy another 1.125M shares at that price.</li><li><a href='https://seekingalpha.com/symbol/VIVE' title='Viveve Medical, Inc.'>VIVE</a>&nbsp;<font color='green'>+3.05%</font>&nbsp;to $4.38 premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3251959\" data-linked=\"Viveve Medical +3% after upsizing capital raise\" data-tweet=\"$VIVE - Viveve Medical +3% after upsizing capital raise https://seekingalpha.com/news/3251959-viveve-medicalplus-3-after-upsizing-capital-raise?source=tweet\" data-url=\"https://seekingalpha.com/news/3251959-viveve-medicalplus-3-after-upsizing-capital-raise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3251957\" data-ts=\"1489753996\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXTI\" target=\"_blank\">AXTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3251957-axtminus-3-pre-market-b-riley-co-downgrades-to-neutral\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AXT -3% pre-market; B. Riley &amp; Co. downgrades to Neutral</a></h4><ul><li>Firm (analyst Dave Kang) recalculates from Buy&nbsp;following AXT's (NASDAQ:<a href='https://seekingalpha.com/symbol/AXTI' title='AXT Inc'>AXTI</a>) disclosure a fire at the company's Beijing plant will likely cause Q1 2017 revenue to register $1.5M-$2M below what had previously been forecasted (revised to $18M-$18.5M from $19.5M-$20M). Notes consideration for possible setback of 3D sensing opportunity.</li><li>Price target from $8.25 to $7 (pre-market $6.40).</li><li>Yesterday (March 16, 2017): <a href=\"https://seekingalpha.com/news/3251749-axt-minus-15_2-percent-fire-beijing-facility-impacts-manufacturing-production\" target=\"_blank\">AXT -15.2%, fire at Beijing facility impacts manufacturing production</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3251957\" data-linked=\"AXT -3% pre-market; B. Riley &amp; Co. downgrades to Neutral\" data-tweet=\"$AXTI - AXT -3% pre-market; B. Riley &amp; Co. downgrades to Neutral https://seekingalpha.com/news/3251957-axtminus-3-pre-market-b-riley-co-downgrades-to-neutral?source=tweet\" data-url=\"https://seekingalpha.com/news/3251957-axtminus-3-pre-market-b-riley-co-downgrades-to-neutral\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3251955\" data-ts=\"1489753420\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STLD\" target=\"_blank\">STLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3251955-steel-dynamics-sees-q1-earnings-above-consensusplus-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Steel Dynamics sees Q1 earnings above consensus; +4% premarket</a></h4><ul><li>Steel Dynamics (NASDAQ:<a href='https://seekingalpha.com/symbol/STLD' title='Steel Dynamics, Inc.'>STLD</a>)&nbsp;<font color='green'>+4.3%</font> premarket after <a href=\"https://seekingalpha.com/pr/16774169-steel-dynamics-provides-first-quarter-2017-guidance-announces-first-quarter-2017-cash\" target=\"_blank\">issuing above consensus guidance</a> for Q1 earnings, seeing EPS of of $0.77-$0.81 vs. analyst expectations for $0.62.</li><li>STLD expects Q1 profitability from steel operations to meaningfully increase from Q4, based on both higher shipments and metal spread  expansion, with higher earnings driven by its flat roll operations, as  demand remains strong and customer inventory levels continue to be  positioned at historically low levels.</li><li>STLD also declares a  quarterly cash <a href=\"https://seekingalpha.com/news/3251871-steel-dynamics-declares-0_155-dividend\" target=\"_blank\">dividend</a> of $0.155/share, an 11% increase over the 2016 quarterly rate.</li><li><a href=\"https://seekingalpha.com/news/3251670-nucor-plus-3-percent-premarket-guiding-q1-earnings-far-consensus\" target=\"_blank\">Yesterday</a>, Nucor also issued a strong Q1 earnings outlook.</li></ul><div class=\"tiny-share-widget\" data-id=\"3251955\" data-linked=\"Steel Dynamics sees Q1 earnings above consensus; +4% premarket\" data-tweet=\"$STLD - Steel Dynamics sees Q1 earnings above consensus; +4% premarket https://seekingalpha.com/news/3251955-steel-dynamics-sees-q1-earnings-above-consensusplus-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3251955-steel-dynamics-sees-q1-earnings-above-consensusplus-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3251954\" data-ts=\"1489753393\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLBS\" target=\"_blank\">CLBS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3251954-caladrius-biosciences-up-nearly-50-after-asset-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Caladrius Biosciences up nearly 50% after asset sale</a></h4><ul><li>Alongside <a href=\"https://seekingalpha.com/news/3251911-caladrius-biosciences-beats-0_07-beats-revenue\" target=\"_blank\">a Q4 earnings beat</a>, the company last night announced the sale of its remaining 80.1% stake in its PCT subsidiary to Hitachi Chemical (which owns the other 19.9%) for $75M in cash. A revenue milestone could allow for another $5M payment.</li><li>Closing is expected in May.</li><li>Proceeds will be used to fund the Phase 2 trial for CLBS03, and the pay off the company's remaining $5.5M in outstanding debt.</li><li>A <a href=\"http://www.caladrius.com/events\" target=\"_blank\">conference call</a> is set for 8:30 ET.</li><li><a href='https://seekingalpha.com/symbol/CLBS' title='Caladrius Biosciences, Inc.'>CLBS</a>&nbsp;<font color='green'>+46%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3251954\" data-linked=\"Caladrius Biosciences up nearly 50% after asset sale\" data-tweet=\"$CLBS - Caladrius Biosciences up nearly 50% after asset sale https://seekingalpha.com/news/3251954-caladrius-biosciences-up-nearly-50-after-asset-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3251954-caladrius-biosciences-up-nearly-50-after-asset-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3251950\" data-ts=\"1489753018\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AFSI\" target=\"_blank\">AFSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3251950-amtrust-needs-time-for-filing-sharesminus-2_8-pre\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AmTrust needs more time for filing; shares -2.8% pre</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/16774006-amtrust-financial-services-inc-provides-update-10-k-filing\" target=\"_blank\">Additional time is required</a> for the company and its auditor to complete their work. The 10-K will be filed as soon as is practicable.</li><li>The delay and restatement for 2014 and 2015 largely relate to the timing of recognition of revenue in AmTrust's (NASDAQ:<a href='https://seekingalpha.com/symbol/AFSI' title='AmTrust Financial Services, Inc.'>AFSI</a>) service and fee business, which is still expected to remain profitable in those years and 2016.</li><li>KBW bull Meyer Shields suspends his rating, price target, and earnings estimates until the restated results.</li><li>Shares&nbsp;<font color='red'>-2.8%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3251950\" data-linked=\"AmTrust needs more time for filing; shares -2.8% pre\" data-tweet=\"$AFSI - AmTrust needs more time for filing; shares -2.8% pre https://seekingalpha.com/news/3251950-amtrust-needs-time-for-filing-sharesminus-2_8-pre?source=tweet\" data-url=\"https://seekingalpha.com/news/3251950-amtrust-needs-time-for-filing-sharesminus-2_8-pre\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3251927\" data-ts=\"1489750472\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TIF\" target=\"_blank\">TIF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3251927-solid-results-from-tiffany\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Solid results from Tiffany</a></h4><ul> <li>Tiffany (NYSE:<a href='https://seekingalpha.com/symbol/TIF' title='Tiffany & Co.'>TIF</a>) reports better comparables sales in Europe, Asia Pacific and the Americas than expected for <a href=\"https://seekingalpha.com/pr/16774257-tiffany-reports-full-year-fourth-quarter-2016-results-sales-earnings-line-previous-guidance\" target=\"_blank\">Q4</a>. Total revenue was up 2% on a constant-currency basis.</li> <li>Gross margin improved 110 bps to 64.1% of sales during the quarter as favorable product input costs factored in.</li> <li>SG&amp;A expenses were 6% higher in Q4 and were 41.5% of sales vs. 38.5% last year.</li> <li>The company paid in effective tax rate of 36.0% vs. 34.4% a year ago.</li> <li>Tiffaney ended the quarter with a merchandise inventory position down 3% Y/Y.</li> <li>Looking ahead, Tiffany sees sales increasing at a low single-digit rate and EPS increasing by a high-single-digit pace vs. +3% consensus. Net cash of $700M and free cash flow of $450M are also expected.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3251904-tiffany-beats-0_07-beats-revenue\" target=\"_blank\">Tiffany beats by $0.07, beats on revenue</a> (March 17)</li> <li>TIF <font color='green'>+2.52%</font> premarket to $92.25.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3251927\" data-linked=\"Solid results from Tiffany\" data-tweet=\"$TIF - Solid results from Tiffany https://seekingalpha.com/news/3251927-solid-results-from-tiffany?source=tweet\" data-url=\"https://seekingalpha.com/news/3251927-solid-results-from-tiffany\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3251925\" data-ts=\"1489750054\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTEM\" target=\"_blank\">MTEM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3251925-threshold-pharmaplus-64-on-merger-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Threshold Pharma +64% on merger deal</a></h4><ul><li>Threshold Pharmaceuticals (THLD) and privately held Molecular Templates agree to merge in an all-stock deal.</li><li>Alongside, venture capital player Longitude Capital will invest $20M at the close of the merger, assuming other equity commitments of $20M.</li><li>Molecular Templates&rsquo; lead product candidate, MT-3724, is an ETB that targets the CD20 cell surface antigen present in a variety of lymphomas and leukemias. A Phase 1 trial with the drug demonstrated good safety and efficacy in elderly, heavily pre-treated patients.</li><li>A <a href=\"http://investor.thresholdpharm.com/events.cfm\" target=\"_blank\">conference call</a> is set for 8:30 ET.</li><li>THLD&nbsp;<font color='green'>+64%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3251925\" data-linked=\"Threshold Pharma +64% on merger deal\" data-tweet=\"$MTEM - Threshold Pharma +64% on merger deal https://seekingalpha.com/news/3251925-threshold-pharmaplus-64-on-merger-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3251925-threshold-pharmaplus-64-on-merger-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3251923\" data-ts=\"1489749725\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EDIT\" target=\"_blank\">EDIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3251923-editas-medicine-prices-90m-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Editas Medicine prices $90M offering</a></h4><ul> <li>Editas Medicine (NASDAQ:<a href='https://seekingalpha.com/symbol/EDIT' title='Editas Medicine'>EDIT</a>) announces that its offering of 4M shares priced at $22.50 per share.</li><li>The proceeds from this offering are expected to be ~$90M.</li><li>Editas Medicine grants the underwriters a 30-day option to purchase up to an additional 600K&nbsp;shares of common stock on the same terms and conditions.</li>   <li>The company says it intends to use the proceeds of the offering to fund preclinical studies and clinical trials for its LCA10 program and its other programs to treat genetic and infectious diseases of the eye, preclinical studies of its programs to treat non-malignant hematologic diseases, preclinical studies in its collaboration with Juno Therapeutics, preclinical studies of other research programs, continued expansion of its platform technology and for working capital.</li>  <li>The offering is expected to close on March 22.</li><li>EDIT  <font color='red'>-2.85%</font> premarket to  $24.20.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16774179-editas-medicine-inc-announces-pricing-90-million-offering-common-stock\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3251923\" data-linked=\"Editas Medicine prices $90M offering\" data-tweet=\"$EDIT - Editas Medicine prices $90M offering https://seekingalpha.com/news/3251923-editas-medicine-prices-90m-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3251923-editas-medicine-prices-90m-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3251920\" data-ts=\"1489749506\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLS\" target=\"_blank\">SLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3251920-galena-pharmaplus-30-after-presentation-of-positive-data-for-galeminus-301-e39\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Galena Pharma +30% after presentation of positive data for GALE-301 (E39)</a></h4><ul><li>\"This final data from our early stage clinical trial demonstrates that GALE-301 is well tolerated and we were able to obtain statistically significant disease free survival in a small number of patients treated with the optimal dose,&rdquo; says Chief Medical Officer Bijan Nejadnik.</li><li><a href=\"https://seekingalpha.com/pr/16774291-galena-biopharma-presents-positive-final-galeminus-301-e39-phase-1-2a-clinical-trial-data\" target=\"_blank\">Full details here</a></li><li>GALE&nbsp;<font color='green'>+30.65%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3251920\" data-linked=\"Galena Pharma +30% after presentation of positive data for GALE-301 (E39)\" data-tweet=\"$SLS - Galena Pharma +30% after presentation of positive data for GALE-301 (E39) https://seekingalpha.com/news/3251920-galena-pharmaplus-30-after-presentation-of-positive-data-for-galeminus-301-e39?source=tweet\" data-url=\"https://seekingalpha.com/news/3251920-galena-pharmaplus-30-after-presentation-of-positive-data-for-galeminus-301-e39\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3251904\" data-ts=\"1489747425\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TIF\" target=\"_blank\">TIF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3251904-tiffany-beats-0_07-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tiffany beats by $0.07, beats on revenue</a></h4><ul><li>Tiffany (NYSE:<a href='https://seekingalpha.com/symbol/TIF' title='Tiffany & Co.'>TIF</a>): Q4 EPS of $1.45 <font color='green'>beats by $0.07</font>.</li><li>Revenue of $1.23B (+1.7% Y/Y) <font color='green'>beats by $10M</font>.</li><li>Shares <font color='green'>+1.6%</font> PM.</li><li><a href='https://seekingalpha.com/pr/16774257-tiffany-reports-full-year-fourth-quarter-2016-results-sales-earnings-line-previous-guidance'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3251904\" data-linked=\"Tiffany beats by $0.07, beats on revenue\" data-tweet=\"$TIF - Tiffany beats by $0.07, beats on revenue https://seekingalpha.com/news/3251904-tiffany-beats-0_07-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3251904-tiffany-beats-0_07-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:43 AM </div></div></li>","count":46,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}